Lybalvi?

Quote

anonymous

Guest
Lybalvi? What genius come up with these names? I can't decide whether to make a bad joke about Alkermes being LIABLE when the patient becomes opiate addicted or a sophomoric joke about LABIA! The real joke is that we think the minuscule difference in wait gain will help us market this drug.

Here is our new slogan..."Ask your doctor if Lybalvi is right for you. Sure you might become opiate addicted, but instead of gaining 50 pounds you'll only gain 48!"
 






I think you mean "weight" gain...but I take your point. The fact that this product contains Samidorphan is like waiving a red flag in front of a bull when it comes to the FDA. Did we learn nothing from the 5461 debacle? Even if we get approval it will be with so many warnings that it will make sales ten time harder. Time for more bonuses in the C suite!
 






anonymous said:
Lybalvi? What genius come up with these names? I can't decide whether to make a bad joke about Alkermes being LIABLE when the patient becomes opiate addicted or a sophomoric joke about LABIA! The real joke is that we think the minuscule difference in wait gain will help us market this drug.

Here is our new slogan..."Ask your doctor if Lybalvi is right for you. Sure you might become opiate addicted, but instead of gaining 50 pounds you'll only gain 48!


We’re all entitled to our opinion about the brand name, and i agree with you, it’s not that great (IMHO)

However, the MOA is not a matter of opinion: it’s not an opiate, it’s an opiate blocker.

Since it’s not an opiate, there is no concern about opiate addiction. Listen to whole presentation, it might help you understand better.

Just trying to help you be a better troll on the internet. Internet trolls are funnier when they have the facts straight (IMHO)
Click to expand...
 






anonymous said:
I think you mean "weight" gain...but I take your point. The fact that this product contains Samidorphan is like waiving a red flag in front of a bull when it comes to the FDA. Did we learn nothing from the 5461 debacle? Even if we get approval it will be with so many warnings that it will make sales ten time harder. Time for more bonuses in the C suite!
Click to expand...

The problem with 5461 wasn’t samidorphan. The problem was efficacy. It didn’t work.

The data made it clear it didn’t work, but we pursued approval anyway, not once but twice. Both were bad decisions that wasted tremendous amounts of money and did a lot of damage to our credibility.

A long time ago ALKS tested a drug for opiate induced constipation. The data showed clearly it didn’t work, so ALKS dropped it and walked away. That was a good decision. Don’t waste time and money on an obvious dead end. Should have done the same thing with 5461.
 






So...Alkermes gets what should be wonderful news from the FDA and our stock soars...right? Meh, not so much. Three months ago today our stock was at 19.69 and now its at 17.52. That's a decrease of almost 11% in just one quarter.

Three months ago today the Dow Jones Average was 26,075, and now its 28,837. That's an increase of almost 11%. Could it be that Wall Street know what a moribund mess this company is?
 
























Remember when HHS Secretary Tom Price was going to be a big boon to Alkermes? He visited our Ohio factory in April of 2017 and was supposed to put the weight of the federal government behind expanding the use of Vivitrol. Of course he had to resign in scandal just a few months later for misuse of public funds...so that was sort of a bust. On the day Price visited us, our stock was trading over $58 a share! But hey, it worked out well for Peter Norman. He got a few promotions since then, so I guess its all good.

But we've learned our lesson, right? I'm sure we're not putting all of our eggs in the "R" basket given what the national polls are saying, right? Nope...not us...we don't learn from the past...we just double down! Those polls are just fake news. If anything, our policy folks in DC are more red, red, red Republican than ever.

We better hope Vice President Harris doesn't decide to pick up where she left off a couple of years ago and make Alkermes the pharma poster-child for bad behavior.
 






Alkermes has PLENTY of issues. The one Kamala Harris brought up isn’t one of them. I’m embarrassed for Harris, and she probably is too, which is why she hasn’t brought it up since.
 






K Harris was grandstanding re her comments about Alkermes. While the company did stand to gain from the judicial system encouraging utilization of its product, the end result was beneficial to society in addressing the addiction epidemic.

I find it difficult to take anyone seriously that slept her way to the top.
 


















anonymous said:
Remember when HHS Secretary Tom Price was going to be a big boon to Alkermes? He visited our Ohio factory in April of 2017 and was supposed to put the weight of the federal government behind expanding the use of Vivitrol. Of course he had to resign in scandal just a few months later for misuse of public funds...so that was sort of a bust. On the day Price visited us, our stock was trading over $58 a share! But hey, it worked out well for Peter Norman. He got a few promotions since then, so I guess its all good.

But we've learned our lesson, right? I'm sure we're not putting all of our eggs in the "R" basket given what the national polls are saying, right? Nope...not us...we don't learn from the past...we just double down! Those polls are just fake news. If anything, our policy folks in DC are more red, red, red Republican than ever.

We better hope Vice President Harris doesn't decide to pick up where she left off a couple of years ago and make Alkermes the pharma poster-child for bad behavior.
Click to expand...


Now that our DC government relations office has absolutely no one on staff with ties to the Democratic party do you think maybe Waltham will start to question the wisdom of leaving a right-wing true-believer Trumpie like Peter Norman in charge of dealing with congress and the Biden administration?
 












This drug is going nowhere, just like Aristada. My KOLs don't have much respect for the way they just "use other company's molecules and package them up as their own. The only thing they can hang their hat on is their delivery systems."

Can't really argue with them.
 






This drug is going nowhere, just like Aristada. My KOLs don't have much respect for the way they just "use other company's molecules and package them up as their own. The only thing they can hang their hat on is their delivery systems."

Can't really argue with them.
 






anonymous said:
This drug is going nowhere, just like Aristada. My KOLs don't have much respect for the way they just "use other company's molecules and package them up as their own. The only thing they can hang their hat on is their delivery systems."

Can't really argue with them.
Click to expand...


Alkermes has its problems but delivery systems is not one of them.

If you can’t make the case for how one delivery system is better than another you are not a very good salesperson.
 






anonymous said:
Alkermes has its problems but delivery systems is not one of them.

If you can’t make the case for how one delivery system is better than another you are not a very good salesperson.
Click to expand...

I don't think they were saying anything negative about our delivery systems. It's our lack of innovation on the product development end.
 






anonymous said:
Lybalvi? What genius come up with these names? I can't decide whether to make a bad joke about Alkermes being LIABLE when the patient becomes opiate addicted or a sophomoric joke about LABIA! The real joke is that we think the minuscule difference in wait gain will help us market this drug.

Here is our new slogan..."Ask your doctor if Lybalvi is right for you. Sure you might become opiate addicted, but instead of gaining 50 pounds you'll only gain 48!"
Click to expand...

Sounds like someone needs to get laid or Quarantine has really given you mental problems. FOH
 






Top Bottom
Back
Quote